Pasar al contenido principal

ESTRATEGIAS FRONTERA MEDIANTE TRASPLANTES FECALES: METABOTIPOS DE POLIFENOLES ASOCIADOS A LA MICROBIOTA INTESTINAL, RIESGO CARDIOMETABOLICO Y DETERIORO COGNITIVO

PID2019-103914RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 28
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives

  • Ávila-Gálvez, María Ángeles
  • Giménez-Bastida, J. A.
  • Espín de Gea, Juan Carlos
  • González-Sarrías, Antonio
© 2020 by the authors., Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in adult women worldwide. Over 85% of BC cases are non-hereditary, caused by modifiable extrinsic factors related to lifestyle, including dietary habits, which play a crucial role in cancer prevention. Although many epidemiological and observational studies have inversely correlated the fruit and vegetable consumption with the BC incidence, the involvement of their phenolic content in this correlation remains contradictory. During decades, wrong approaches that did not consider the bioavailability, metabolism, and breast tissue distribution of dietary phenolics persist behind the large currently existing gap between preclinical and clinical research. In the present review, we provide comprehensive preclinical and clinical evidence according to physiologically relevant in vitro and in vivo studies. Some dietary phenolics such as resveratrol (RSV), quercetin, isoflavones, epigallocatechin gallate (EGCG), lignans, and curcumin are gaining attention for their chemopreventive properties in preclinical research. However, the clinical evidence of dietary phenolics as BC chemopreventive compounds is still inconclusive. Therefore, the only way to validate promising preclinical results is to conduct clinical trials in BC patients. In this regard, future perspectives on dietary phenolics and BC research are also critically discussed, This research was funded by the projects PID2019-103914RB-I00 (MICINN, Spain), 19900/GERM/15 (Fundación Séneca de la Región de Murcia, Spain), and 201870E014 and 201770E081 (CSIC, Spain). J.A.G.B. was supported by a Juan de la Cierva contract (IJCI-2016-27633) from the Ministry of Science, Innovation and Universities (Spain) and a Standard European Marie Curie Fellowship from the European Commission. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 838991., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evidence for health properties of pomegranate juices and extracts beyond nutrition: A critical systematic review of human studies

  • Giménez-Bastida, J. A.
  • Ávila-Gálvez, María Ángeles
  • Espín de Gea, Juan Carlos
  • González-Sarrías, Antonio
Background The consumption of pomegranate juices and extracts has long been linked to many health benefits beyond nutrition, described mainly by innumerable preclinical studies. However, the European Food Safety Authority (EFSA) concluded in 2010 that a cause and effect relationship could not be established between the consumption of pomegranate-derived products and all the health claims presented. There are no additional EFSA opinions on health claims specifically addressed to pomegranate in the last decade. Scope and approach This review comprehensively compiles all human studies conducted on pomegranate. The aim is to discuss these studies critically to identify possible flaws and propose guidelines that might help establish a cause and effect relationship between pomegranate-derived product consumption and health. Key findings and conclusions To date, 86 human studies have evaluated the health benefits of pomegranate juices and extracts. The most promising, albeit scarce, evidence is related to blood pressure improvement. Less evidence deals with inflammation, cancer, cognitive function, physical activity, and gut microbiota modulation (prebiotic effects). After a decade since EFSA's opinion, human evidence remains inconsistent, making it difficult to support most claimed health effects. The lack of effects and(or) data discrepancy might be attributable to design limitations, including insufficient product characterization and interindividual variability that influence pomegranate polyphenols' bioefficacy. New coordinated strategies between policy makers, research/academic institutions, and industry are needed to move forward. Therefore, this review presents a roadmap to conduct well-designed trials and cover existing gaps, which could establish a cause-effect relation between pomegranate consumption and health benefits beyond nutrition., This work was supported by the MICINN (Spain) under grant number [PID2019-103914RB-I00], and by the European Union's Horizon 2020 research and innovation programme under the Marie Curie Sklodowska-Curie Grant Agreement [No 838991]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Disposition of Dietary Polyphenols in Breast Cancer Patients’ Tumors, and Their Associated Anticancer Activity: The Particular Case of Curcumin

  • Ávila-Gálvez, María Ángeles
  • González-Sarrías, Antonio
  • Martínez-Díaz, Francisco
  • Abellán, Beatriz
  • Martínez-Torrano, Alejandro José
  • Fernández-López, Antonio José
  • Giménez-Bastida, J. A.
  • Espín de Gea, Juan Carlos
Scope: Some polyphenol-derived metabolites reach human breast cancer (BC) tissues at concentrations that induce cell senescence. However, this is unknown for isoflavones, curcuminoids, and lignans. Here, their metabolic profiling in normal (NT) and malignant (MT) mammary tissues of newly-diagnosed BC patients and the tissue-occurring metabolites’ anticancer activity are evaluated. Methods and results: Patients (n = 26) consumed 3 capsules/day (turmeric, red clover, and flaxseed extracts plus resveratrol; 296.4 mg phenolics/capsule) from biopsy-confirmed diagnosis to surgery (5 ± 2 days) or did not consume capsules (n = 13). NT and MT, blood, and urine are analyzed by UPLC-QTOF-MS using targeted metabolomics. Anticancer activity was tested in MCF-7 and MDA-MB-231 BC cells. Mainly phase-II metabolites were detected (108, 84, 49, and 47 in urine, plasma, NT, and MT, respectively). Total metabolite concentrations reached 10.7 ± 11.1 and 2.5 ± 2.4 µmol L in NT and MT, respectively. Free curcumin, but not its glucuronide, was detected in the tissues (1.1 ± 1.8 and 0.2 ± 0.2 µmol L in NT and MT, respectively). Breast tissue-occurring metabolites’ antiproliferation was mainly exerted in p53-wild-type MCF-7 cells by curcuminoids through cell cycle arrest, senescence, and apoptosis induction via p53/p21 induction, while isoflavone-derived metabolites exerted estrogenic-like activity. Conclusion: Curcuminoids could be coadjuvants that might help fight BC upon regular consumption., This research was supported by the Projects 201770E081 from the Spanish National Research Council (CSIC, Spain) and by PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICINN, Spain). J.A.G.-B. was supported by a Standard European Marie Curie Fellowship from the European Commission. This project received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 838991
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacological Therapy Determines the Gut Microbiota Modulation by a Pomegranate Extract Nutraceutical in Metabolic Syndrome: A Randomized Clinical Trial

  • Cortés-Martín, Adrián
  • Iglesias-Aguirre, Carlos E.
  • Selma, María Victoria
  • Espín de Gea, Juan Carlos
Scope: Poly-pharmacological therapy shapes the gut microbiota (GM) in metabolic syndrome (MetS) patients. The effects of polyphenols in poly-medicated MetS patients are unknown. Methods and results: A randomized, placebo-controlled, double-blinded, and crossover trial in poly-medicated MetS patients (n=50) explored whether the effects of a pomegranate extract nutraceutical (PE, 320 mg phenolics/day for 1 month) are affected by the drug therapy. Considering the lipid-lowering (LL-), anti-hypertensive (HP-) and(or) anti-diabetic (AD-) treatments: GM (16S rRNA sequencing), short-chain fatty acids, 40 inflammatory-metabolic and endotoxemia-related biomarkers, associations between biomarkers and GM with 53 cardiometabolic dysfunctions-related single-nucleotide polymorphisms (SNPs), and urolithin metabotypes (UMs) influence are evaluated. Representative SNPs-GM associations after PE include Lactococcus and ClostridiumXIVa with rs5443-GNB3 (G-protein-β-polypeptide-3) and ClostridiumXIVa with rs7903146-TCF7L2 (transcription-factor-7-like-2) and rs1137101-LEPR (leptin-receptor). PE decreases sICAM-1 in LL-patients and the lipopolysaccharide-binding protein in all the patients. PE does not affect the other patients’ markers as a group or stratifying by UMs. After PE, Lactococcus increases in AD-, LL-, and HP-patients, Bifidobacterium increases in LL- and AD-, while Clostridium XIVa decreases in non-LL- and non-HP-patients. Conclusion: The prebiotic effect of PE depends on the medication, mainly on HP-treatments. Targeting GM can complement MetS therapy, but the patients’ drug therapy should be considered individually., Ministerio de Economía y Competitividad. Grant Number: AGL2015-94124-R Fundación Séneca. Grant Number: 20880/PI/18 Ministerio de Ciencia e Innovación. Grant Number: PID2019-103914RB-I00
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Main drivers of (poly)phenol effects on human health: Metabolite production and/or gut microbiota-associated metabotypes?

  • Iglesias-Aguirre, Carlos E.
  • Cortés-Martín, Adrián
  • Ávila-Gálvez, María Ángeles
  • Giménez-Bastida, J. A.
  • Selma, María Victoria
  • González-Sarrías, Antonio
  • Espín de Gea, Juan Carlos
Despite the high human interindividual variability in response to (poly)phenol consumption, the cause-and-effect relationship between some dietary (poly)phenols (flavanols and olive oil phenolics) and health effects (endothelial function and prevention of LDL oxidation, respectively) has been well established. Most of the variables affecting this interindividual variability have been identified (food matrix, gut microbiota, single-nucleotide-polymorphisms, etc.). However, the final drivers for the health effects of (poly)phenol consumption have not been fully identified. At least partially, these drivers could be (i) the (poly)phenols ingested that exert their effect in the gastrointestinal tract, (ii) the bioavailable metabolites that exert their effects systemically and/or (iii) the gut microbial ecology associated with (poly)phenol metabolism (i.e., gut microbiota-associated metabotypes). However, statistical associations between health effects and the occurrence of circulating and/or excreted metabolites, as well as cross-sectional studies that correlate gut microbial ecologies and health, do not prove a causal role unequivocally. We provide a critical overview and perspective on the possible main drivers of the effects of (poly)phenols on human health and suggest possible actions to identify the putative actors responsible for the effects., This research was supported by the Project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICINN, Spain) and by Fundación Séneca de la Región de Murcia (Spain), grant number 20880/PI/18. J.A.G.-B. was supported by a Standard European Marie Curie Fellowship from the European Commission. This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 838991. A.C.M. and C.E.I.-A. are the holders of predoctoral grants from MINECO (grant number BES-2016-078098) and MICINN (grant number FPU18/03961) (Spain), respectively, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differential effects of western and mediterranean-type diets on gut microbiota: A metagenomics and metabolomics approach

  • Barber, Claudia
  • Mego, Marianela
  • Sabater, Carlos
  • Vallejo, Fernando
  • Bendezu, Rogger Alvaro
  • Masihy, Marcela
  • Guarner, Francisco
  • Espín de Gea, Juan Carlos
  • Margolles Barros, Abelardo
  • Azpiroz, Fernando
Our aim was to determine the effect of diet on gut microbiota, digestive function and sensations, using an integrated clinical, metagenomics and metabolomics approach. We conducted a cross-over, randomised study on the effects of a Western-type diet versus a fibre-enriched Mediterranean diet. In 20 healthy men, each diet was administered for 2 weeks preceded by a 2-week washout diet. The following outcomes were recorded: (a) number of anal gas evacuations; (b) digestive sensations; (c) volume of gas evacuated after a probe meal; (d) colonic content by magnetic resonance imaging; (e) gut microbiota taxonomy and metabolic functions by shotgun sequencing of faecal samples; (f) urinary metabolites using untargeted metabolomics. As compared to a Western diet, the Mediterranean diet was associated with (i) higher number of anal gas evacuations, (ii) sensation of flatulence and borborygmi, (iii) larger volume of gas after the meal and (iv) larger colonic content. Despite the relatively little difference in microbiota composition between both diets, microbial metabolism differed substantially, as shown by urinary metabolite profiles and the abundance of microbial metabolic pathways. The effects of the diet were less evident in individuals with robust microbiotas (higher beta-diversity). To conclude, healthy individuals tolerate dietary changes with minor microbial modifications at the composition level but with remarkable variation in microbial metabolism., The present study was supported by the projects SAF 2016-76648-R (Ministerio de Economia y Competitividad, Dirección General de Investigación Científica y Técnica, Spain), PID2019- 103914RB-I00 (Ministerio de Ciencia e Innovación, Spain), AGL2016-78311-R (Ministerio de Ciencia e Innovación, Spain) and FJC2019-042125-I (Ministerio de Ciencia e Innovación, Spain). Ciberehd is funded by the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Bioactive Peptides

  • Santos-Hernández, Marta
  • Miralles, Beatriz
  • Hernández-Ledesma, Blanca
  • Amigo, Lourdes
  • Recio, Isidra
This chapter aims to bring together some of the available methods to identify and quantify bioactive peptides in food or biological matrices, and to evaluate biological activities either in vitro or in vivo. Among others, bioactive peptides may be involved in enzyme inhibition, channel blockade, radical or metal scavenging, electrostatic or hydrophobic interaction, or receptor activation, making possible to acknowledge antihypertensive, antidiabetic, antimicrobial, cyto- and immunomodulatory, or antioxidant activities. Bioactive peptides from milk proteins are considered as food ingredients that promote human health, although in some cases they may also have detrimental effects such as the case of food peptides constituting allergenic epitopes. Although high-performance liquid chromatography-MS is a powerful technique for peptide sequencing, certain RP separations entail some difficulties, for instance, the identification of small hydrophilic peptides eluting in the first part of the chromatogram, which is usually discarded to avoid salts entering into the mass spectrometer., This work has received financial support from project AGL2015–66886-R from the Spanish Ministry of Economy and Competitiveness (MINECO) and PID2019–107663RB-100 and PID2019-103919RB-100 from the Spanish Ministry of Science and Innovation. M. S.-H. is the recipient of FPU grant (FPU15–03616) from the Ministry of Education, Culture and Sports., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Antioxidant, anti-inflammatory, and immunomodulatory effects of soybean peptide lunasin in macrophages and lymphocytes models

  • Paterson, Samuel
  • Fernández-Tomé, Samuel
  • Indiano-Romacho, Pedro
  • Hernández-Ledesma, Blanca
Resumen del trabajo presentado a la XII International Conference on Immunonutrition (ICI), celebrada on-line del 14 al 16 de julio de 2021., This research was funded by projects AGL2015‐ 66886‐R (Spanish Ministry of Science and Innovation, MICIU) and PID2019‐103919RB‐100 (CSIC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Hepatocarcinoma-associated pathways modulated by soybean peptide lunasin

  • Fernández-Tomé, Samuel
  • Indiano-Romacho, Pedro
  • Paterson, Samuel
  • Gálvez, Alfredo
  • Hernández-Ledesma, Blanca
Resumen del trabajo presentado a la 29th International Conference of FFC - 17th International Symposium of ASFFBC: "Functional Foods, Bioactive Compounds and Biomarkers for Aging and Related Diseases", celebradas on-line del 20 al 21 de septiembre de 2021., This work has received financial support from projects AGL2015‐66886‐R (Spanish Ministry of Science and Innovation, MICIU) and PID2019‐103919RB‐100 (CSIC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exosome-Containing Extracellular Vesicles Contribute to the Transport of Resveratrol Metabolites in the Bloodstream: A Human Pharmacokinetic Study

  • Iglesias-Aguirre, Carlos E.
  • Ávila-Gálvez, María Ángeles
  • López de las Hazas, María-Carmen
  • Dávalos Herrera, Alberto
  • Espín de Gea, Juan Carlos
Exosomes are extracellular vesicles (EVs) that regulate intercellular signaling by transferring small RNAs, proteins, nucleic acids, lipids, and other metabolites to local or distant organs, including the brain, by crossing the blood–brain barrier. However, the transport of (poly)phenols in human EVs has not yet been described. Therefore, we aimed here to explore (i) whether resveratrol and (or) its derived metabolites are found in the cargo of human plasma exosome-containing EVs (E-EVs), (ii) when this incorporation occurs, and (iii) whether resveratrol intake stimulates the release of E-EVs. Thus, in a pharmacokinetic study, healthy volunteers (n = 16) consumed 1 capsule (420 mg resveratrol) in the evening before attending the clinic and one more capsule on the day of the pharmacokinetics. The plasma and the isolated E-EVs were analyzed using UPLC-ESI-QTOF-MS. Of 17 metabolites in the plasma, 9 were identified in the E-EVs, but not free resveratrol. The kinetic profiles of resveratrol metabolites were similar in the plasma and the E-EVs, a higher metabolite concentration being detected in the plasma than in the E-EVs. However, the plasma/E-EVs ratio decreased in the gut microbial metabolites, suggesting their better encapsulation efficiency in E-EVs. In addition, glucuronide conjugates of resveratrol, dihydroresveratrol, and lunularin were incorporated into the E-EVs more efficiently than their corresponding sulfates despite glucuronides reaching lower plasma concentrations. Notably, more E-EVs were detected 10 h after resveratrol consumption. This exploratory study provides the first evidence that (i) resveratrol metabolites are transported by E-EVs, with a preference for glucuronide vs. sulfates, (ii) the gut microbial metabolites concentration and kinetic profiles are closely similar in E-EVs and plasma, and (iii) resveratrol intake elicits E-EVs secretion. Overall, these results open new research avenues on the possible role of E-EVs in (poly)phenol health effects., This research was supported by the Projects PID2019-103914RB-I00 and PID2019-109369RB-I00 from the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033, Spain). C.E.I.-A. is the holder of a predoctoral grant FPU18/03961 from MICIN. M.C.L.-H. is a receipt of a Juan de la Cierva Grant IJC2020-044353-I/MCIN/AEI/10.13039/501100011033/EU/PRTR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients

  • Romo Vaquero, María
  • Fernández-Villalba, Emiliano
  • Gil-Martínez, Ana-Luisa
  • Cuenca-Bermejo, Lorena
  • Espín de Gea, Juan Carlos
  • Herrero, María Trinidad
  • Selma, María Victoria
Gut microbiota alteration (gut dysbiosis) occurs during the onset and progression of Parkinson's disease. Gut dysbiosis biomarkers could be relevant to prodromal disease. Urolithins, anti-inflammatory metabolites produced from some dietary polyphenols by specific gut microbial ecologies (urolithin metabotypes), have been proposed as biomarkers of gut microbiota composition and functionality. However, this has not been explored in Parkinson's disease patients. The current study aimed to assess associations between urolithin metabotypes, gut dysbiosis and disease severity in Parkinson's disease patients. Participants (52 patients and 117 healthy controls) provided stool samples for microbiota sequencing and urine samples for urolithin profiling before and after consuming 30 g of walnuts for three days. Data on demographics, medication, disease duration and Hoehn and Yahr disease stage were collected. We observed a significant gradual increase of urolithin non-producers (metabotype-0) as the disease severity increased. The gut microbiome of metabotype-0 patients and patients with the greatest severity was characterized by a more altered bacterial composition, i.e., increased pro-inflammatory Enterobacteriaceae and reduced protective bacteria against autoimmune and inflammatory processes, including butyrate and urolithin-producing bacteria (Lachnospiraceae members and Gordonibacter). Besides, their microbiome was characterized by predictive functions of lipopolysaccharide biosynthesis and metabolism of glutathione, cysteine and methionine that could indirectly reflect the gut pro-inflammatory status. Urolithin detection in urine is a feasible, non-invasive and fast approach that can reflect gut microbiome dysbiosis and intestinal inflammation in Parkinson's disease patients. Our current study could provide novel strategies for improving diagnostics, and for preventing and treating disease progression in microbiota-based interventions., This research has been supported by the projects AGL2015- 64124-R and PID2019-103914RB-I00 (Spanish Ministry of Science and Innovation), PIE-201570I005 (Spanish National Research Council) and FS/20880/PI/18 (Fundación Séneca, Spain). The authors are grateful to the Murcia Federation of Parkinson’s disease
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Physiologically relevant curcuminoids inhibit angiogenesis via VEGFR2 in human aortic endothelial cells

  • Giménez-Bastida, J. A.
  • Ávila-Gálvez, María Ángeles
  • Carmena-Bargueño, Miguel
  • Pérez-Sánchez, Horacio
  • Espín de Gea, Juan Carlos
  • González-Sarrías, Antonio
Angiogenesis is a complex process encompassing endothelial cell proliferation, migration, and tube formation. While numerous studies describe that curcumin exerts antitumor properties (e.g., targeting angiogenesis), information regarding other dietary curcuminoids such as demethoxycurcumin (DMC) and bisdemethoxycurcumin (BisDMC) is scant. In this study, we evaluated the antiangiogenic activities of these three curcuminoids at physiological concentrations (0.1¿5 ¿M) on endothelial cell migration and tubulogenesis and the underlying associated mechanisms on human aortic endothelial cells (HAECs). Results showed that the individual compounds and a representative mixture inhibited the tubulogenic and migration capacity of endothelial cells dose-dependently, while sparing cell viability. Notably, DMC and BisDMC at 0.1 and 1 ¿M showed higher capacity than curcumin inhibiting tubulogenesis. These compounds also reduced phosphorylation of the VEGFR2 and the downstream ERK and Akt pathways in VEGF165-stimulated cells. In silico analysis showed that curcuminoids could bind the VEGFR2 antagonizing the VEGF-mediated angiogenesis. These findings suggest that physiologically concentrations of curcuminoids might counteract pro-angiogenic stimuli relevant to tumorigenic processes., J.A.G.-B. was supported by Standard European Marie Curie Individual Fellowship from the European Commission. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Grant Agreement No 838991, and by the project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICINN, Spain)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

4-Hydroxydibenzyl: a novel metabolite from the human gut microbiota after consuming resveratrol

  • Iglesias-Aguirre, Carlos E.
  • Vallejo, Fernando
  • Beltrán Riquelme, David
  • Berná, José
  • Puigcerver, J.
  • Alajarín, Mateo
  • Selma, María Victoria
  • Espín de Gea, Juan Carlos
Resveratrol (RSV) was known to be metabolised by the gut microbiota to dihydroresveratrol, lunularin (LUNU), and (or) 3,4′-dihydroxy-trans-stilbene (DHST). We describe here for the first time that LUNU can be further dehydroxylated, but only at the 3-position, to yield 4-hydroxydibenzyl, a novel metabolite found in human urine after RSV intake in 41 out of 59 healthy participants. In contrast, DHST was not further dehydroxylated, and thus, 4-hydroxy-trans-stilbene was not detected as a gut microbial metabolite of RSV. Faecal in vitro incubations confirmed the in vivo results., This research has been supported by Project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICINN, Spain). C. E. I. A. and J. P. are the holders of predoctoral grants FPU18/03961 and FPU19/05419, respectively, from MICINN
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting Mammalian 5-Lipoxygenase by Dietary Phenolics as an Anti-Inflammatory Mechanism: A Systematic Review

  • Giménez-Bastida, J. A.
  • González-Sarrías, Antonio
  • Laparra, José Moisés
  • Schneider, Claus
  • Espín de Gea, Juan Carlos
This article belongs to the Collection Feature Papers in Bioactives and Nutraceuticals., 5-Lipoxygenase (5-LOX) plays a key role in inflammation through the biosynthesis of leukotrienes and other lipid mediators. Current evidence suggests that dietary (poly)phenols exert a beneficial impact on human health through anti-inflammatory activities. Their mechanisms of action have mostly been associated with the modulation of pro-inflammatory cytokines (TNF-α, IL-1β), prostaglandins (PGE2), and the interaction with NF-κB and cyclooxygenase 2 (COX-2) pathways. Much less is known about the 5-lipoxygenase (5-LOX) pathway as a target of dietary (poly)phenols. This systematic review aimed to summarize how dietary (poly)phenols target the 5-LOX pathway in preclinical and human studies. The number of studies identified is low (5, 24, and 127 human, animal, and cellular studies, respectively) compared to the thousands of studies focusing on the COX-2 pathway. Some (poly)phenolics such as caffeic acid, hydroxytyrosol, resveratrol, curcumin, nordihydroguaiaretic acid (NDGA), and quercetin have been reported to reduce the formation of 5-LOX eicosanoids in vitro. However, the in vivo evidence is inconclusive because of the low number of studies and the difficulty of attributing effects to (poly)phenols. Therefore, increasing the number of studies targeting the 5-LOX pathway would largely expand our knowledge on the anti-inflammatory mechanisms of (poly)phenols., This research was supported by the project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICINN, Spain). J.A.G.-B. was supported by a Standard European Marie Curie Fellowship from the European Commission. This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 838991. CS is supported by NIH awards GM076592 and GM118412., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota

  • García-Villalba, Rocío
  • Giménez-Bastida, J. A.
  • Cortés-Martín, Adrián
  • Ávila-Gálvez, María Ángeles
  • Tomás Barberán, Francisco
  • Selma, María Victoria
  • Espín de Gea, Juan Carlos
  • González-Sarrías, Antonio
Urolithins, metabolites produced by the gut microbiota from the polyphenols ellagitannins and ellagic acid, are discovered by the research group in humans almost 20 years ago. Pioneering research suggests urolithins as pleiotropic bioactive contributors to explain the health benefits after consuming ellagitannin-rich sources (pomegranates, walnuts, strawberries, etc.). Here, this study comprehensively updates the knowledge on urolithins, emphasizing the review of the literature published during the last 5 years. To date, 13 urolithins and their corresponding conjugated metabolites (glucuronides, sulfates, etc.) have been described and, depending on the urolithin, detected in different human fluids and tissues (urine, blood, feces, breastmilk, prostate, colon, and breast tissues). There has been a substantial advance in the research on microorganisms involved in urolithin production, along with the compositional and functional characterization of the gut microbiota associated with urolithins metabolism that gives rise to the so-called urolithin metabotypes (UM-A, UM-B, and UM-0), relevant in human health. The design of in vitro studies using physiologically relevant assay conditions (molecular forms and concentrations) is still a pending subject, making some reported urolithin activities questionable. In contrast, remarkable progress has been made in the research on the safety, bioactivity, and associated mechanisms of urolithin A, including the first human interventions., This research was supported by the Project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICINN, Spain) and the Projects 20880/PI/18 and 19900/GERM/15 (Fundación Séneca de la Región de Murcia, Spain). J.A.G.-B. was supported by a Standard European Marie Curie Fellowship from the European Commission. This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 838991., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lunularin Producers versus Non-producers: Novel Human Metabotypes Associated with the Metabolism of Resveratrol by the Gut Microbiota

  • Iglesias-Aguirre, Carlos E.
  • Vallejo, Fernando
  • Beltrán Riquelme, David
  • Aguilar-Aguilar, Elena
  • Puigcerver, J.
  • Alajarín, Mateo
  • Berná, José
  • Selma, María Victoria
  • Espín de Gea, Juan Carlos
We describe here for the first time the consistent observation of two metabotypes associated with resveratrol metabolism by the human gut microbiota, that is, lunularin (LUNU)-producers and LUNU non-producers. In healthy volunteers (n = 195), resveratrol was reduced to dihydroresveratrol, which only in the LUNU-producer metabotype was sequentially dehydroxylated at the 5-position to yield LUNU and the 3-position to produce 4-hydroxydibenzyl. These metabolites (also 3,4′-dihydroxy-trans-stilbene in some LUNU-producers) were detected in the urine and (or) feces of 74% of volunteers after consuming resveratrol, while 26% lacked these dehydroxylase activities. The LUNU non-producer metabotype was more prevalent in females (P < 0.05) but independent of individuals' BMI and age. A 4-styrylphenol reductase in both metabotypes converted stilbenes to their corresponding dibenzyls, while no 4-dehydroxylation in stilbenes or dibenzyls was observed. 4-Hydroxy-trans-stilbene, pinosylvin, dihydropinosylvin, 3-hydroxydibenzyl, and 3-hydroxy-trans-stilbene were not detected in vivo or in vitro. Further research on LUNU metabotypes, their associated gut microbiota, and their impact on health is worthwhile., This research was supported by Project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033, Spain). The authors are grateful to Adrián Cortés-Martín and M. Ángeles Ávila-Gálvez for their help in some parts of the study. C.E.I.-A. and J.P. are the holders of predoctoral grants FPU18/03961 and FPU19/05419, respectively, from MICINN
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effect of Resistant Dextrin on Intestinal Gas Homeostasis and Microbiota

  • Barber, Claudia
  • Sabater, Carlos
  • Ávila-Gálvez, María Ángeles
  • Vallejo, Fernando
  • Bendezu, Rogger Alvaro
  • Guérin-Deremaux, Laetitia
  • Guarner, Francisco
  • Espín de Gea, Juan Carlos
  • Margolles Barros, Abelardo
  • Azpiroz, Fernando
Previous studies have shown that a resistant dextrin soluble fibre has prebiotic properties with related health benefits on blood glucose management and satiety. Our aim was to demonstrate the effects of continuous administration of resistant dextrin on intestinal gas production, digestive sensations, and gut microbiota metabolism and composition. Healthy subjects (n = 20) were given resistant dextrin (14 g/d NUTRIOSE®, Roquette Frères, Lestrem, France) for four weeks. Outcomes were measured before, at the beginning, end, and two weeks after administration: anal evacuations of gas during daytime; digestive perception, girth, and gas production in response to a standard meal; sensory and digestive responses to a comfort meal; volume of colonic biomass by magnetic resonance; taxonomy and metabolic functions of fecal microbiota by shotgun sequencing; metabolomics in urine. Dextrin administration produced an initial increase in intestinal gas production and gas-related sensations, followed by a subsequent decrease, which magnified after discontinuation. Dextrin enlarged the volume of colonic biomass, inducing changes in microbial metabolism and composition with an increase in short chain fatty acids-producing species and modulation of bile acids and biotin metabolism. These data indicate that consumption of a soluble fibre induces an adaptative response of gut microbiota towards fermentative pathways with lower gas production., This work was supported by a grant from Roquette. The research activities were supported in part by the projects PID2021-122295OB-I00 (Ministerio de Ciencia e Innovación, Spain), PID2019-103914RB-I00 (Ministerio de Ciencia e Innovación, Spain), AGL2016-78311-R (Ministerio de Ciencia e Innovación, Spain) and FJC2019-042125-I (Ministerio de Ciencia e Innovación, Spain). Ciberehd is funded by the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ellagitannins, urolithins, and neuroprotection: Human evidence and the possible link to the gut microbiota

  • García-Villalba, Rocío
  • Tomás Barberán, Francisco
  • Iglesias-Aguirre, Carlos E.
  • Giménez-Bastida, J. A.
  • González-Sarrías, Antonio
  • Selma, María Victoria
  • Espín de Gea, Juan Carlos
Ellagitannins (ETs) and ellagic acid (EA) are dietary polyphenols poorly absorbed but extensively metabolized by the human gut microbiota to produce different urolithins (Uros). Depending on the individuals' microbial signatures, ETs metabolism can yield the Uro metabotypes A, B, or 0, potentially impacting human health after consuming ETs. Human evidence points to improved brain health after consuming ET-rich foods, mainly pomegranate juices and extracts containing punicalagin, punicalin, and different EA-derivatives. Although ETs and (or) EA are necessary to exert the effects, the precise mechanism, actual metabolites, or final drivers responsible for the observed effects have not been unraveled. The cause-and-effect evidence on Uro-A administration and the improvement of animal brain health is consistent but not addressed in humans. The Uro-A's in vivo anti-inflammatory, mitophagy, autophagy, and mitochondrial biogenesis activities suggest it as a possible final driver in neuroprotection. However, the precise Uro metabolic forms reaching the brain are unknown. In addition to the possible participation of direct effectors in brain tissues, the current evidence points out that improving blood flow, gut microbiota ecology, and gut barrier by ET-rich foods and (or) Uro-A could contribute to the neuroprotective effects. We show here the current human evidence on ETs and brain health, the possible link between the gut microbiota metabolism of ETs and their effects, including the preservation of the gut barrier integrity, and the possible role of Uros. Finally, we propose a roadmap to address what is missing on ETs, Uros, and neuroprotection, This work was supported by the Projects PID 2019-103914RB-I00 from the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033, Spain) and 21647/PDC/21, 20880/PI/18 and 19900/GERM/15 (Fundación Séneca de la Región de Murcia, Spain). C.E.I.-A. holds a predoctoral grant from MICIN (grant number FPU18/03961, Spain). J.A.G.-B. was supported by a Standard European Marie Curie Fellowship from the European Commission (European Union's Horizon, 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 838991)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gut Bacteria Involved in Ellagic Acid Metabolism To Yield Human Urolithin Metabotypes Revealed

  • Iglesias-Aguirre, Carlos E.
  • García-Villalba, Rocío
  • Beltrán Riquelme, David
  • Frutos-Lisón, M.D.
  • Espín de Gea, Juan Carlos
  • Tomás Barberán, Francisco
  • Selma, María Victoria
We aimed to elucidate the gut bacteria that characterize the human urolithin metabotypes A and B (UM-A and UM-B). We report here a new bacterium isolated from the feces of a healthy woman, capable of producing the final metabolites urolithins A and B and different intermediates. Besides, we describe two gut bacterial co-cultures that reproduced the urolithin formation pathways upon in vitro fermentation of both UM-A and UM-B. This is the first time that the capacity of pure strains to metabolize ellagic acid cooperatively to yield urolithin profiles associated with UM-A and UM-B has been demonstrated. The urolithin-producing bacteria described herein could have potential as novel probiotics and in the industrial manufacture of bioactive urolithins to develop new ingredients, beverages, nutraceuticals, pharmaceuticals, and (or) functional foods. This is especially relevant in UM-0 individuals since they cannot produce bioactive urolithins, This work has been funded by the Project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICIN, AEI/10.13039/501100011033, Spain) and Projects 21647/PDC/21 and 20880/PI/18 (Fundación Séneca de la Región de Murcia, Spain). The study was also funded by CSIC PIE 202270E057 and the Neuroaging PTI+ platform. C.E.I.-A. is the holder of a predoctoral grant from MICIN (grant number FPU18/03961), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Milk-Derived Exosomes as Nanocarriers to Deliver Curcumin and Resveratrol in Breast Tissue and Enhance Their Anticancer Activity

  • González-Sarrías, Antonio
  • Iglesias-Aguirre, Carlos E.
  • Cortés-Martín, Adrián
  • Vallejo, Fernando
  • Cattivelli, Alice
  • Pozo-Acebo, Lorena del
  • Saz, Andrea del
  • López de las Hazas, María-Carmen
  • Dávalos Herrera, Alberto
  • Espín de Gea, Juan Carlos
Dietary (poly)phenols are extensively metabolized, limiting their anticancer activity. Exosomes (EXOs) are extracellular vesicles that could protect polyphenols from metabolism. Our objective was to compare the delivery to breast tissue and anticancer activity in breast cancer cell lines of free curcumin (CUR) and resveratrol (RSV) vs. their encapsulation in milk-derived EXOs (EXO-CUR and EXO-RSV). A kinetic breast tissue disposition was performed in rats. CUR and RSV were analyzed using UPLC-QTOF-MS and GC-MS, respectively. Antiproliferative activity was tested in MCF-7 and MDA-MB-231 breast cancer and MCF-10A non-tumorigenic cells. Cell cycle distribution, apoptosis, caspases activation, and endocytosis pathways were determined. CUR and RSV peaked in the mammary tissue (41 ± 15 and 300 ± 80 nM, respectively) 6 min after intravenous administration of EXO-CUR and EXO-RSV, but not with equivalent free polyphenol concentrations. Nanomolar EXO-CUR or EXO-RSV concentrations, but not free CUR or RSV, exerted a potent antiproliferative effect on cancer cells with no effect on normal cells. Significant (p < 0.05) cell cycle alteration and pro-apoptotic activity (via the mitochondrial pathway) were observed. EXO-CUR and EXO-RSV entered the cells primarily via clathrin-mediated endocytosis, avoiding ATP-binding cassette transporters (ABC). Milk EXOs protected CUR and RSV from metabolism and delivered both polyphenols to the mammary tissue at concentrations compatible with the fast and potent anticancer effects exerted in model cells. Milk EXOs enhanced the bioavailability and anticancer activity of CUR and RSV by acting as Trojan horses that escape from cancer cells’ ABC-mediated chemoresistance., This research was supported by the projects PID2019-103914RB-I00, PID2019-109369RB-I00, and RTI2018-093873-A-I00 from the Ministry of Science and Innovation (MICINN, Spain) and European FEDER funds. C.E.I.-A. is the holder of a predoctoral grant (FPU18/03961) from MICINN (Spain). M.C.L.H. is a recipient of a Juan de la Cierva Grant IJC2020-044353-I/MCIN/AEI/10.13039/501100011033/EU/PRTR (MICINN, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vivo administration of gut bacterial consortia replicates urolithin metabotypes A and B in a non-urolithin-producing rat model

  • Iglesias-Aguirre, Carlos E.
  • González-Sarrías, Antonio
  • Cortés-Martín, Adrián
  • Romo Vaquero, María
  • Osuna-Galisteo, Leire
  • Cerón, José J.
  • Espín de Gea, Juan Carlos
Urolithin (Uro) production capacity and, consequently, at least partly, the health effects attributed to ellagitannin and ellagic acid consumption vary among individuals. The reason is that not all individuals have the gut bacterial ecology needed to produce the different Uro metabolites. Three human urolithin metabotypes (UM-A, UM-B, and UM-0) based on dissimilar Uro production profiles have been described in populations worldwide. Recently, the gut bacterial consortia involved in ellagic acid metabolism to yield the urolithin-producing metabotypes (UM-A and UM-B) in vitro have been identified. However, the ability of these bacterial consortia to customize urolithin production to mimic UM-A and UM-B in vivo is still unknown. In the present study, two bacterial consortia were assessed for their capacity to colonize the intestine of rats and convert UM-0 (Uro non-producers) animals into Uro-producers that mimic UM-A and UM-B, respectively. Two consortia of Uro-producing bacteria were orally administered to non-urolithin-producing Wistar rats for 4 weeks. Uro-producing bacterial strains effectively colonized the rats’ gut, and the ability to produce Uros was also effectively transferred. Bacterial strains were well tolerated. No changes in other gut bacteria, except Streptococcus reduction, or adverse effects on haematological and biochemical parameters were observed. Besides, two novel qPCR procedures were designed and successfully optimized to detect and quantify Ellagibacter and Enterocloster genera in faecal samples. These results suggest that the bacterial consortia are safe and could be potential probiotics for human trials, which is especially relevant for UM-0 individuals, who cannot produce bioactive Uros, This work has been funded by the project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICIN, AEI/10.13039/501100011033, Spain) and Projects 21647/PDC/21 and 20880/PI/18 (Fundación Séneca de la Región de Murcia, Spain). C. E. I.-A. is the holder of a predoctoral grant from MICIN (grant number FPU18/03961), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitophagy curtails cytosolic mtDNAdependent activation of cGAS/STING inflammation during aging

  • Jiménez-Loygorri, Juan Ignacio
  • Villarejo-Zori, Beatriz
  • Viedma-Poyatos, Álvaro
  • Zapata-Muñoz, Juan
  • Benítez-Fernández, Rocío
  • Frutos-Lisón, M.D.
  • Tomás Barberán, Francisco
  • Espín de Gea, Juan Carlos
  • Area-Gomez, Estela
  • Gómez-Durán, Aurora
  • Boya, Patricia
15 p.-8 fig., Macroautophagy decreases with age, and this change is considered a hallmark of the aging process. It remains unknown whether mitophagy, the essential selective autophagic degradation of mitochondria, also decreases with age. In our analysis of mitophagy in multiple organs in the mito-QC reporter mouse, mitophagy is either increased or unchanged in old versus young mice. Transcriptomic analysis shows marked upregulation of the type I interferon response in the retina of old mice, which correlates with increased levels of cytosolic mtDNA and activation of the cGAS/STING pathway. Crucially, these same alterations are replicated in primary human fibroblasts from elderly donors. In old mice, pharmacological induction of mitophagy with urolithin A attenuates cGAS/STING activation and ameliorates deterioration of neurological function. These findings point to mitophagy induction as a strategy to decrease age-associated inflammation and increase healthspan., Research in the P.B. lab is supported by grants 310030_215271 Swiss National Science Foundation (SNSF) and PID2021-126864NB I00 from MCIN, Spain. Research in J.C.E lab is supported by PID2019-103914RB-I00 from MICIN (MCIN/AEI/10.13039/501100011033, Spain, Unión Europea NextGenerationEU/PRTR). Both labs are also supported by CSIC Interdisciplinary Thematic Platform PTI-NEURO-AGING+ of the Spanish National Research Council (CSIC) and funded B.V.Z. Research in the AGD lab is supported by grants PID2020-114709RA-I00 and RYC2020-029291-I from MICIN and IDEAS222813GOME from AECC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unveiling metabotype clustering in resveratrol, daidzein, and ellagic acid metabolism: Prevalence, associated gut microbiomes, and their distinctive microbial networks

  • Iglesias-Aguirre, Carlos E.
  • Romo Vaquero, María
  • Selma, María Victoria
  • Espín de Gea, Juan Carlos
The gut microbiota (GM) produces different polyphenol-derived metabolites, yielding high interindividual variability and hampering consistent health effects. GM metabotypes associated with ellagic acid (urolithin metabotypes A (UMA), B (UMB), and 0 (UM0)), resveratrol (lunularin -producers (LP) and non-producers (LNP)), and daidzein (equol-producers (EP) and non-producers (ENP)) are known. However, individual polyphenol-related metabotypes do not occur individually. In contrast, different combinations coexist (i.e., metabotype clusters, MCs). We report here for the first time these MCs, their distribution, and their associated GM in adult humans (n = 127) after consuming for 7 days a nutraceutical (pomegranate, Polygonum cuspidatum, and red clover extracts) containing ellagitannins + ellagic acid, resveratrol, and isoflavones. Urine metabolites (UHPLC-QTOF-MS) and fecal microbiota (16S rRNA sequencing) were analyzed. Ten MCs were identified: LP + UMB + ENP (22.7%), LP + UMA + ENP (21.3%), LP + UMA + EP (16.7%), LP + UMB + EP (16%), LNP + UMA + ENP (11.3%), LNP + UMB + ENP (5.3%), LNP + UMA + EP (3.3%), LNP + UMB + EP (2%), LNP + UM0 + EP (0.7%), and LNP + UM0 + ENP (0.7%). Sex, BMI, and age did not affect the distribution of metabotypes or MCs. Multivariate analysis (MaAslin2) revealed genera differentially present in individual metabotypes and MCs. Network analysis (MENA) showed the taxa acting as module hubs and connectors. Compositional and functional profiling, alpha and beta diversities, topological network features, and GM modulation by the nutraceutical differed depending on whether the entire cohort or each MC was considered. The nutraceutical did not change the composition of LP + UMA + EP (the most robust GM with the most associated functions) but increased its network connectors. This pioneering approach, joining GM’s compositional, functional, and network features in polyphenol metabolism, paves the way for identifying personalized GM-targeted strategies to improve polyphenol health benefits, This research was supported by Project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICIN/ AEI /https://doi.org/10.13039/501100011033, Spain). C. E. I.-A. holds a predoctoral grant from MICIN (grant number FPU18/03961), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NMR Spectroscopic Identification of Urolithin G, a Novel Trihydroxy Urolithin Produced by Human Intestinal Enterocloster Species

  • Beltrán Riquelme, David
  • Frutos-Lisón, M.D.
  • García-Villalba, Rocío
  • Yuste, Jose E.
  • García-Aparicio, Víctor
  • Espín de Gea, Juan Carlos
  • Selma, María Victoria
  • Tomás Barberán, Francisco
Urolithins are gut microbiota metabolites of ellagic acid. Here, we have identified and chemically characterized a novel urolithin produced from urolithin D (3,4,8,9-tetrahydroxy urolithin) by in vitro incubation with different human gut Enterocloster species under anaerobic conditions. Urolithin G (3,4,8-trihydroxy urolithin) was identified by 1H NMR, 13C NMR, UV, HRMS, and 2D NMR. For the identification, NMR spectra of other known urolithins were also recorded and compared. Urolithin G was present in the feces of 12% of volunteers in an overweight-obese group after consuming an ellagitannin-rich pomegranate extract. The production of urolithin G required a bacterial 9-dehydroxylase activity and was not specific to the known human urolithin metabotypes A and B. The ability to produce urolithin G could be considered an additional metabolic feature for volunteer stratification and bioactivity studies. This is the first urolithin with a catechol group in ring A while having only one hydroxyl in ring B, a unique feature not found in human and animal samples so far, This work has been funded by the Project PID2019-103914RB-I00 from the Ministry of Science and Innovation (MICIN, AEI/10.13039/501100011033, Spain) and Projects 21647/PDC/21 and 20880/PI/18 (Fundación Séneca de la Región de Murcia, Spain), and CSIC PIE 202270E057, and the Neuroaging Platform, and the AGROALNEXT program supported by MCIN with funding from the European Union NextGenerationEU (PRTR-C17.I1) and Fundación Séneca, Comunidad Autónoma Región de Murcia (CARM), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effects of a (poly)phenol-rich berry mix on gas production in healthy individuals: An integrated clinical, metagenomic, and metabolomic proof-of-concept study

  • Barber, Claudia
  • Sabater, Carlos
  • Frutos, María Dolores
  • Vallejo, Fernando
  • Guyonnet, Denis
  • Daniel, Noëmie
  • Guarner, Francisco
  • Espín de Gea, Juan Carlos
  • Margolles Barros, Abelardo
  • Azpiroz, Fernando
Dietary (poly)phenols are metabolized by intestinal microbiota, but their potential effect on intestinal gas production and gas-reated symptoms remain uncertain. The aim of this study was to correlate gas production, digestive sensations, gut microbiota composition, and metabolites in urine and feces upon (poly)phenols consumption. Twenty-three healthy subjects consumed a (poly)phenol-rich berry mix for 18 days. The (poly)phenol-rich mix initially increased anal gas evacuation and induced gas-related sensations, which reverted by 18 days of dietary administration, indicating that they were metabolized and induced an adaptation of the microbiota. Upon consumption, microbiota composition adapted, exhibiting significant correlations between some taxa, bile acids, and digestive sensations, like L. pectinoschiza, positively associated with digestive well-being. Notably, the steroid-like metabolite cortolone decreased 7-fold (p < 0.001), and the bile acid 7-ketodeoxycholic acid decreased 5-fold (p < 0.001) in the urine. These preliminary data suggest that consumption of a (poly)phenol-rich berry mix induces an adaptation of the gut microbiota with beneficial effects on gas-related sensations, This work was supported by a grant from Symrise AG (Diana Food Inc.). The research activities were partially supported by the projects PID2021-122295OB-I00, PID2019-103914RB-I00, and AGL2016-78311-R (Ministry of Science and Innovation, MICIN, AEI /https://doi.org/10.13039/501100011033, Spain), and by FJC2019-042125-I (MICIN). Ciberehd is funded by the Instituto de Salud Carlos III, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

El activador de autofagia urolitina A y su viaje al cerebro: lecciones de un modelo de envejecimiento fisiológico en ratones

  • Espín de Gea, Juan Carlos
  • Jiménez-Loygorri, Juan Ignacio
  • Viedma-Poyatos, Álvaro
  • Frutos-Lisón, M.D.
  • Tomás-Barberán, Francisco Abraham
  • Boya, Patricia
Antecedentes y objetivo: Existe controversia para identificar qué metabolito final ejerce actividad biológica tras el consumo de polifenoles. El ácido elágico (nueces, fresas, granada, etc.) es metabolizado por la microbiota intestinal hasta urolitinas, metabolitos anti-inflamatorios, antiproliferativos, neuroprotectores, moduladores de la microbiota intestinal y protectores de la barrera intestinal. Urolitina-A (Uro-A) induce autofagia en modelos murinos de enfermedades del sistema nervioso central (SNC). Sin embargo, se desconoce si llega al parénquima cerebral para ejercer estos efectos. Nuestro objetivo es explorar los efectos de Uro-A en un modelo de ratón de envejecimiento fisiológico y comprobar si Uro-A y/o sus metabolitos de fase-II llegan al cerebro. Métodos y resultados: Administramos 2,3 mg de Uro-A i.p. diariamente (~14 mg/persona de 70 kg) en ratones jóvenes (6 m) y viejos (22 m) durante 8 semanas. Realizamos electrorretinogramas, pruebas de comportamiento, histología de retina, análisis de mitofagia y del metabolismo de Uro-A (UPLC-QTOF-MS). Uro-A mejoró el índice neurodegenerativo, memoria visual, daño oxidativo, integridad sináptica, gliosis, visión nocturna y mitofagia, especialmente en ratones viejos. Un estudio cinético mostró pico de Uro-A, Uro-A-sulfato y Uro-A-glucurónido en plasma, y de forma relevante, Uro-A y Uro-A-sulfato, pero no Uro-A-glucurónido en cerebro perfundido, 30 minutos tras administrar Uro-A. Conclusiones: Uro-A ejerce neuroprotección previniendo deterioro del SNC asociado al envejecimiento. La llegada al cerebro de Uro-A y Uro-A-sulfato tras administrar Uro-A vía i.p., sugiere que cruzan la barrera hematoencefálica. Uro-A-sulfato podría ser un reservorio para liberar Uro-A tras desconjugación por arilsulfatasas cerebrales. Sin embargo, Uro-A-glucurónido, relevante en humanos, no llega al cerebro., NEURO-AGING+ (Plataforma Temática Interdisciplinar del CSIC, PTI+), y PID2019-103914RB-I00 y PGC2018-098557-B-I00 (MICINN, España)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differential effects of western and mediterranean-type diets on gut microbiota, a metagenomics and metabolomics approach

  • Barber Caselles, Claudia|||0000-0003-4711-2731
  • Mego Silva, Marianela
  • Sabater, Carlos|||0000-0002-6098-895X
  • Vallejo, Fernando|||0000-0003-3343-6479
  • Bendezú García, Rogger Álvaro
  • Masihy, Marcela
  • Guarner, Francisco|||0000-0002-4051-0836
  • Espín, Juan Carlos|||0000-0002-1068-8692
  • Margolles, Abelardo
  • Azpiroz Vidaur, Fernando|||0000-0002-7327-960X
Our aim was to determine the effect of diet on gut microbiota, digestive function and sensations, using an integrated clinical, metagenomics and metabolomics approach. We conducted a cross-over, randomised study on the effects of a Western-type diet versus a fibre-enriched Mediterranean diet. In 20 healthy men, each diet was administered for 2 weeks preceded by a 2-week washout diet. The following outcomes were recorded: (a) number of anal gas evacuations; (b) digestive sensations; (c) volume of gas evacuated after a probe meal; (d) colonic content by magnetic resonance imaging; (e) gut microbiota taxonomy and metabolic functions by shotgun sequencing of faecal samples; (f) urinary metabolites using untargeted metabolomics. As compared to a Western diet, the Mediterranean diet was associated with (i) higher number of anal gas evacuations, (ii) sensation of flatulence and borborygmi, (iii) larger volume of gas after the meal and (iv) larger colonic content. Despite the relatively little difference in microbiota composition between both diets, microbial metabolism differed substantially, as shown by urinary metabolite profiles and the abundance of microbial metabolic pathways. The effects of the diet were less evident in individuals with robust microbiotas (higher beta-diversity). To conclude, healthy individuals tolerate dietary changes with minor microbial modifications at the composition level but with remarkable variation in microbial metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of Resistant Dextrin on Intestinal Gas Homeostasis and Microbiota

  • Barber Caselles, Claudia|||0000-0003-4711-2731
  • Sabater, Carlos|||0000-0002-6098-895X
  • Ávila-Gálvez, María Ángeles|||0000-0003-2513-1026
  • Vallejo, Fernando|||0000-0003-3343-6479
  • Bendezú García, Rogger Álvaro
  • Guérin-Deremaux, Laetitia
  • Guarner, Francisco|||0000-0002-4051-0836
  • Espín, Juan Carlos|||0000-0002-1068-8692
  • Margolles, Abelardo
  • Azpiroz Vidaur, Fernando|||0000-0002-7327-960X
Previous studies have shown that a resistant dextrin soluble fibre has prebiotic properties with related health benefits on blood glucose management and satiety. Our aim was to demonstrate the effects of continuous administration of resistant dextrin on intestinal gas production, digestive sensations, and gut microbiota metabolism and composition. Healthy subjects (n = 20) were given resistant dextrin (14 g/d NUTRIOSE ®, Roquette Frères, Lestrem, France) for four weeks. Outcomes were measured before, at the beginning, end, and two weeks after administration: anal evacuations of gas during daytime; digestive perception, girth, and gas production in response to a standard meal; sensory and digestive responses to a comfort meal; volume of colonic biomass by magnetic resonance; taxonomy and metabolic functions of fecal microbiota by shotgun sequencing; metabolomics in urine. Dextrin administration produced an initial increase in intestinal gas production and gas-related sensations, followed by a subsequent decrease, which magnified after discontinuation. Dextrin enlarged the volume of colonic biomass, inducing changes in microbial metabolism and composition with an increase in short chain fatty acids-producing species and modulation of bile acids and biotin metabolism. These data indicate that consumption of a soluble fibre induces an adaptative response of gut microbiota towards fermentative pathways with lower gas production.